Study design1,2

Clinical efficacy was evaluated in a randomized, double-masked, placebo-controlled trial in patients who received either DEXYCU (342 mcg n=158; 517 mcg n=156) or a vehicle administered by a physician at the end of the surgical procedure (placebo n=80) (N=394). Use of ocular, periocular, or systemic corticosteroids, immunomodulators, alkylating agents, or ocular topical NSAIDs was not allowed through day 30 unless necessary; glaucoma and other ocular medications (including topical cyclosporine but excluding ocular topical NSAIDs) could be administered peri- and postoperatively as indicated. Patients who received corticosteroids or immunosuppressants for any condition (ocular or systemic) were followed through 90 days. The primary endpoint was the proportion of patients with complete AC cell clearing (cell score=0) on postoperative day 8.